In the ever-evolving global landscape of cell therapy development, selecting quality rawmaterials is crucial for achieving clinical and commercial milestones. In this Innovator Insightarticle, Kyle Hondorp asks industry experts, Kasey Kime and Lili Belcastro, to share insightsinto the key factors influencing raw material selection throughout different phases of development. Kyle Hondorp also discusses the Gibco™ Cell Therapy Systems (CTS™) portfolio offit-for-purpose media and reagents, cell therapy instrumentation, and viral vector systems,which are GMP manufactured, safety tested, and backed by regulatory documentation tosupport cell and gene therapy developers along their path to commercialization.